TNFSF12 Gene (TWEAK)

TNFSF12 Gene (TWEAK)

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">TNFSF12 Gene (TWEAK)</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>TNFSF12</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>TNFSF12 (TWEAK)</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=TNFSF12" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/atherosclerosis" style="color:#ef9a9a">Atherosclerosis</a>, <a href="/wiki/dementia" style="color:#ef9a9a">Dementia</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">23 edges</a></td>
</tr>
</table>

TNFSF12 Gene (TWEAK)

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">TNFSF12 Gene (TWEAK)</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>TNFSF12</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>TNFSF12 (TWEAK)</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=TNFSF12" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/atherosclerosis" style="color:#ef9a9a">Atherosclerosis</a>, <a href="/wiki/dementia" style="color:#ef9a9a">Dementia</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">23 edges</a></td>
</tr>
</table>

TNFSF12 (TNF Superfamily Member 12) encodes the cytokine TWEAK (TNF-like Weak Inducer of Apoptosis), a pleiotropic member of the tumor necrosis factor superfamily. Originally identified in 1997, TWEAK has emerged as a critical regulator of multiple biological processes including cell survival, proliferation, migration, inflammation, and tissue repair.[@sarrias2012] In the nervous system, TWEAK plays particularly important roles in neuroinflammation, astrocyte biology, blood-brain barrier function, and the pathogenesis of multiple sclerosis, Alzheimer's disease, and other neurological disorders.[@hu2015]

TWEAK signals through binding to its sole receptor Fn14 (TNFRSF12A), a member of the TNF receptor superfamily.[@winkles2008] This binding activates multiple signaling pathways including NF-κB, MAPK, and caspase-dependent apoptotic pathways, allowing TWEAK to exert diverse effects depending on the cellular context and microenvironment. The TWEAK-Fn14 axis has attracted significant attention as a potential therapeutic target, with antagonistic antibodies and decoy receptors under development for various inflammatory and neoplastic conditions.

In the brain, TWEAK is produced by multiple cell types including [astrocytes](/cell-types/astrocytes), [microglia](/cell-types/microglia-neuroinflammation), [neurons](/entities/neurons), and infiltrating immune cells. The receptor Fn14 is induced by injury, inflammation, and disease, creating a context-dependent signaling axis that can be protective or pathogenic depending on the specific pathological conditions. Elevated TWEAK levels have been documented in multiple sclerosis, Alzheimer's disease, Parkinson's disease, brain ischemia, and traumatic brain injury, suggesting a broad involvement in neurological disease processes.

Pathway / Interaction Diagram

Gene Structure and Organization

Genomic Location and Architecture

The human TNFSF12 gene is located on chromosome 17p13.1, spanning approximately 4 kb of genomic DNA. The gene consists of 4 exons encoding a type II transmembrane protein that can be proteolytically cleaved to generate a soluble cytokine form. This genomic organization is typical of TNF superfamily members, which generally contain small numbers of exons encoding relatively compact proteins.

The TNFSF12 promoter contains binding sites for multiple transcription factors including NF-κB, AP-1, and STAT1, enabling regulation by inflammatory signals. The gene exhibits relatively constitutive expression in various tissues, with higher levels in certain cell types and upregulation in response to inflammatory cytokines and cellular stress.

Evolutionary Conservation

TNFSF12 is evolutionarily conserved across mammals, with orthologs identified in mice, rats, and other vertebrates. The protein shows moderate conservation within the TNF superfamily, sharing structural features and functional properties with other family members while maintaining unique aspects of its biology.

The TWEAK-Fn14 axis appears to be a relatively recent evolutionary innovation, with clear orthologs present in mammals but less conserved representations in lower vertebrates. This evolutionary pattern suggests specialized functions in mammalian physiology and disease.

Protein Structure and Function

Protein Architecture

TWEAK is a type II transmembrane protein with the following structural features:

Transmembrane region:

• N-terminal transmembrane helix anchors TWEAK to the cell surface
• Enables presentation of TWEAK in a membrane-bound form with distinct biological activities
• Can be proteolytically cleaved to generate soluble TWEAK

• C-terminal extracellular domain contains the receptor-binding site
• Forms the functional cytokine that can be shed from the cell surface
• Contains conserved TNF homology domain (THD) responsible for trimer formation and receptor binding

• Matrix metalloproteinases (MMPs) cleave membrane-bound TWEAK to generate soluble cytokine
• Soluble TWEAK retains biological activity and can act in paracrine and endocrine fashions
• The balance between membrane-bound and soluble TWEAK affects signaling outcomes

Receptor Interaction

TWEAK signals exclusively through Fn14 (TNFRSF12A), distinguishing it from many other TNF family members that signal through multiple receptors:

Fn14 structure:

• Type I transmembrane protein
• Contains a single cysteine-rich domain (CRD) for ligand binding
• Minimal cytoplasmic domain lacking death domains

• Activation of NF-κB (canonical and non-canonical pathways)
• MAPK activation (ERK, JNK, p38)
• PI3K-Akt signaling
• Caspase-dependent apoptosis in certain contexts

• DcR3 (TNFRSF6B) can bind TWEAK as a decoy receptor
• DcR3 expression is induced in inflammation and cancer
• Provides additional regulation of TWEAK bioavailability

Expression Pattern

Cellular Expression

TWEAK is expressed by multiple cell types in the nervous system:

Astrocytes:

• Primary producers of TWEAK in the brain parenchyma
• Expression increased by inflammatory stimuli (IL-1β, TNF-α, IFN-γ)
• Astrocytic TWEAK promotes proliferation and inflammatory responses

• Express TWEAK at lower levels than astrocytes
• May increase expression upon activation
• Contributes to microglial inflammatory responses

• Express TWEAK at baseline in some neuronal populations
• Upregulation in injury and disease states
• May affect neuronal survival and function

• T cells, B cells, and monocytes can produce TWEAK
• Peripheral immune cell infiltration adds to CNS TWEAK pool
• Important in inflammatory demyelinating conditions

Tissue Distribution

Beyond the nervous system, TWEAK is expressed in:

• Liver (hepatocytes)
• Heart (cardiomyocytes)
• Kidney (tubular epithelial cells)
• Skeletal muscle
• Adipose tissue
• Endothelial cells

Biological Functions

Pro-inflammatory Effects

TWEAK potently promotes inflammation in the nervous system:

Cytokine induction:

• Stimulates production of IL-1β, IL-6, TNF-α in astrocytes and microglia
• Promotes chemokine production (CXCL1, CCL2, CCL5)
• Amplifies inflammatory cascades

• Enhances expression of adhesion molecules (ICAM-1, VCAM-1)
• Promotes leukocyte migration across the blood-brain barrier
• Supports infiltration of peripheral immune cells into CNS

• Promotes astrocyte proliferation and reactivity
• Activates microglia to pro-inflammatory phenotype
• Contributes to glial scar formation in injury

Effects on Cell Survival

TWEAK has context-dependent effects on cell survival:

Pro-survival signaling:

• NF-κB activation can promote cell survival
• Can protect certain cell types from apoptotic stimuli
• May support tissue repair processes

• Can induce apoptosis in some cell types
• Particularly relevant in cancer biology
• May contribute to neuronal loss in certain conditions

Blood-Brain Barrier Function

The TWEAK-Fn14 axis significantly affects blood-brain barrier (BBB) integrity:

BBB disruption:

• TWEAK promotes expression of matrix metalloproteinases (MMP-2, MMP-9)
• Increases endothelial cell permeability
• Disrupts tight junction proteins (claudin-5, occludin)

• Enhanced leukocyte transmigration across BBB
• Increased expression of adhesion molecules on endothelial cells
• Contribution to neurovascular unit dysfunction

• TWEAK inhibition may protect BBB integrity
• Relevant for multiple sclerosis, stroke, and traumatic brain injury

Tissue Repair

Despite its pro-inflammatory effects, TWEAK can contribute to tissue repair:

Angiogenesis:

• Promotes endothelial cell migration and tube formation
• Contributes to neovascularization in wound healing
• May be relevant to pathological angiogenesis in cancer

• Stimulates astrocyte proliferation in CNS repair
• Promotes fibroblast proliferation in peripheral tissues
• Supports regenerative processes when appropriately regulated

Role in Neurological Diseases

Multiple Sclerosis

TWEAK is strongly implicated in multiple sclerosis (MS) pathogenesis:

Expression in MS lesions:

• TWEAK and Fn14 are highly expressed in MS brain lesions
• Expression is particularly prominent in active demyelinating lesions
• Astrocytes and microglia are major cellular sources

• Promotes inflammatory demyelination
• Stimulates astrocyte proliferation and gliosis
• Contributes to blood-brain barrier disruption
• May directly affect oligodendrocyte survival

• Anti-TWEAK antibodies have been evaluated in preclinical MS models
• Fn14 antagonists may reduce disease severity
• Clinical trials of TWEAK blockade have been conducted in MS

• TWEAK deficiency or blockade reduces EAE severity
• Reduces inflammatory cell infiltration
• Decreases demyelination

Alzheimer's Disease

TWEAK contributes to Alzheimer's disease pathogenesis:

Expression changes:

• Elevated TWEAK levels in AD brain tissue and cerebrospinal fluid
• Increased expression in astrocytes near amyloid plaques
• Fn14 expression is also upregulated in AD brain

• Promotion of neuroinflammation through glial activation
• Potential effects on amyloid-β metabolism
• Contribution to synaptic dysfunction
• Neuronal viability effects

• TWEAK inhibition may reduce neuroinflammation
• Potential for disease-modifying effects
• May need to balance inflammatory modulation with tissue repair

Parkinson's Disease

Evidence for TWEAK involvement in Parkinson's disease:

Expression alterations:

• TWEAK expression is altered in PD substantia nigra
• Fn14 expression may be affected in dopaminergic neurons
• Changes correlate with disease severity

• Neuroinflammation modulation
• Effects on dopaminergic neuron survival
• Potential impacts on α-synuclein pathology

• Less well-established than in MS and AD
• Further studies needed to clarify TWEAK's role

Brain Ischemia and Stroke

TWEAK is implicated in stroke pathophysiology:

Ischemic injury:

• TWEAK expression increases following cerebral ischemia
• Contributes to post-ischemic inflammation
• May exacerbate neuronal injury

• TWEAK inhibition reduces brain injury in animal models
• Improves functional recovery
• May protect the neurovascular unit

• TWEAK may contribute to blood-brain barrier disruption
• Affects inflammatory responses in hemorrhagic injury

Traumatic Brain Injury

Following traumatic brain injury (TBI):

Temporal pattern:

• TWEAK expression increases early after injury
• Remains elevated during the inflammatory phase
• Correlates with injury severity

• Promotes neuroinflammation
• Contributes to blood-brain barrier disruption
• May affect long-term outcomes

• TWEAK blockade may improve outcomes after TBI
• Reduces secondary brain damage
• May enhance recovery

Interaction Partners and Signaling Pathways

Signaling Pathways

TWEAK activates multiple intracellular signaling cascades:

NF-κB pathway:

• Canonical NF-κB activation through TRAF2/6
• Non-canonical pathway through NF-κB-inducing kinase (NIK)
• Pro-inflammatory gene transcription

• ERK1/2 activation
• JNK/p38 activation
• Cell survival and stress responses

• Akt activation promotes survival
• Cross-talk with other pathways
• Context-dependent effects

Protein Interactions

TWEAK interacts with multiple cellular proteins:

Receptor complex:

• Fn14 with TRAF molecules
• Downstream signaling adaptors

• DcR3 (TNFRSF6B) binds and neutralizes TWEAK
• Provides regulatory mechanism

• RIP1, RIP2 in NF-κB activation
• Caspases in apoptotic signaling
• Various kinase effectors

Therapeutic Implications

Targeting the TWEAK-Fn14 Axis

The TWEAK-Fn14 pathway is a therapeutic target:

Biologics:

• Anti-TWEAK antibodies (e.g., enavatuzumab)
• Fn14-specific antibodies
• Fc-TWEAK fusion proteins (decoy receptors)

• Fn14 antagonists in development
• Inhibitors of TWEAK processing

• Clinical trials in multiple sclerosis completed
• Trials in other inflammatory conditions
• Cancer applications also being explored

Disease-Specific Applications

Multiple sclerosis:

• Most advanced therapeutic application
• Anti-TWEAK antibodies showed promise in preclinical models
• Clinical trials have assessed safety and efficacy

• TWEAK inhibition may reduce neuroinflammation
• Potential disease-modifying effects
• Requires careful consideration of tissue repair functions

• TWEAK blockade is neuroprotective in animal models
• May reduce post-ischemic inflammation
• Translation to clinical practice being explored

Research Methods

Detection and Analysis

Protein detection:

• ELISA for soluble TWEAK measurement
• Western blot for protein expression
• Immunohistochemistry for tissue localization

• RT-PCR and qPCR for gene expression
• In situ hybridization for cellular localization

• Cell proliferation assays
• Cytokine measurement
• Signaling pathway analysis

Animal Models

Genetic models:

• Tnfsf12 knockout mice
• Fn14 knockout mice
• Transgenic overexpression models

• EAE for multiple sclerosis
• Stroke models (MCAO)
• Traumatic brain injury models
• AD and PD models

Therapeutic Development

Drug candidates:

• Monoclonal antibodies against TWEAK
• Fn14-specific antagonists
• Small molecule inhibitors

• Systemic administration
• CNS-penetrant formulations being developed
• Local delivery options

Future Directions

Key questions remaining about TWEAK include:

External Resources

• [NCBI Gene: TNFSF12](https://www.ncbi.nlm.nih.gov/gene/8742)
• [UniProt: TWEAK](https://www.uniprot.org/uniprot/O43508)
• [Ensembl: TNFSF12](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000125655)
• [OMIM: TNFSF12](https://www.omim.org/entry/602732)
• [PubMed: TWEAK neuroinflammation](https://pubmed.ncbi.nlm.nih.gov/?term=TWEAK+neuroinflammation)

Summary

TNFSF12 encodes TWEAK, a pleiotropic cytokine of the TNF superfamily that signals through the Fn14 receptor to regulate multiple biological processes in the nervous system. In the brain, TWEAK is produced by astrocytes, microglia, and neurons, where it promotes neuroinflammation, affects cell survival, and modulates blood-brain barrier function. Elevated TWEAK expression is documented in multiple sclerosis, Alzheimer's disease, Parkinson's disease, brain ischemia, and traumatic brain injury, making the TWEAK-Fn14 axis an attractive therapeutic target.

The pathogenic mechanisms of TWEAK include promotion of glial activation and proliferation, induction of pro-inflammatory cytokines, disruption of blood-brain barrier integrity, and direct effects on neuronal survival. Preclinical studies demonstrate that TWEAK inhibition reduces disease severity in models of multiple sclerosis, stroke, and traumatic brain injury. Clinical trials have explored TWEAK blockade in multiple sclerosis and other conditions, though translation to approved therapies remains ongoing.

As research continues to elucidate the complex biology of the TWEAK-Fn14 axis, the potential for targeting this pathway in neurodegenerative and neuroinflammatory diseases becomes increasingly clear. The challenge lies in harnessing the therapeutic potential while respecting the pathway's context-dependent functions in tissue repair and homeostasis.

References

Pathway Diagram

The following diagram shows the key molecular relationships involving TNFSF12 Gene (TWEAK) discovered through SciDEX knowledge graph analysis: